BRPI0806461B8 - monossal do ácido maleico, e, composição farmacêutica para a prevenção ou tratamento das infecções virais - Google Patents

monossal do ácido maleico, e, composição farmacêutica para a prevenção ou tratamento das infecções virais

Info

Publication number
BRPI0806461B8
BRPI0806461B8 BRPI0806461A BRPI0806461A BRPI0806461B8 BR PI0806461 B8 BRPI0806461 B8 BR PI0806461B8 BR PI0806461 A BRPI0806461 A BR PI0806461A BR PI0806461 A BRPI0806461 A BR PI0806461A BR PI0806461 B8 BRPI0806461 B8 BR PI0806461B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
prevention
treatment
viral infections
maleic acid
Prior art date
Application number
BRPI0806461A
Other languages
English (en)
Inventor
Hye Lee Ji
Min Yun Jung
Sook Park Ki
Original Assignee
Lg Chemical Ltd
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd, Lg Life Sciences Ltd filed Critical Lg Chemical Ltd
Publication of BRPI0806461A2 publication Critical patent/BRPI0806461A2/pt
Publication of BRPI0806461B1 publication Critical patent/BRPI0806461B1/pt
Publication of BRPI0806461B8 publication Critical patent/BRPI0806461B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composto, e, composição farmacêutica para a prevenção ou tratamento das infecções virais. a presente invenção diz respeito a monossal do ácido 3-[({1- [(2-amino-9h-purin-9-il)metil] ciclopropil }óxi)metil] -8,8 -dimetil-3 ,7-dioxo- 2,4,6-trioxa-3(lambda)5 -fosfanon-1-il-pivalato maleico e composição farmacêutica contendo o mesmo.
BRPI0806461A 2007-01-17 2008-01-11 monossal do ácido maleico, e, composição farmacêutica para a prevenção ou tratamento das infecções virais BRPI0806461B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20070005269 2007-01-17
KR10-2007-0005269 2007-01-17
PCT/KR2008/000194 WO2008088147A1 (en) 2007-01-17 2008-01-11 Maleic acid monosalt of antiviral agent and pharmaceutical composition containing the same

Publications (3)

Publication Number Publication Date
BRPI0806461A2 BRPI0806461A2 (pt) 2011-09-06
BRPI0806461B1 BRPI0806461B1 (pt) 2019-09-03
BRPI0806461B8 true BRPI0806461B8 (pt) 2021-05-25

Family

ID=39636116

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0806461A BRPI0806461B8 (pt) 2007-01-17 2008-01-11 monossal do ácido maleico, e, composição farmacêutica para a prevenção ou tratamento das infecções virais

Country Status (17)

Country Link
US (1) US20090325904A1 (pt)
EP (1) EP2124953A4 (pt)
JP (1) JP4980431B2 (pt)
KR (1) KR100935904B1 (pt)
CN (1) CN101616674B (pt)
AR (1) AR064915A1 (pt)
BR (1) BRPI0806461B8 (pt)
CA (1) CA2673510C (pt)
CL (1) CL2008000070A1 (pt)
CO (1) CO6210809A2 (pt)
EA (1) EA015269B1 (pt)
MX (1) MX2009006826A (pt)
MY (1) MY163479A (pt)
TW (1) TWI384986B (pt)
UA (1) UA91655C2 (pt)
WO (1) WO2008088147A1 (pt)
ZA (1) ZA200904378B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
CN107109497A (zh) * 2014-12-31 2017-08-29 豪夫迈·罗氏有限公司 通过实时PCR从细胞裂解物定量HBV cccDNA的高通量新方法
CN106977548A (zh) * 2016-01-19 2017-07-25 四川海思科制药有限公司 倍司福韦复合物及其制备方法和用途
KR102623581B1 (ko) * 2016-07-18 2024-01-11 일동제약(주) 항바이러스성 약물의 오로트산염, 이의 제조 방법 및 상기 염을 포함하는 약제학적 조성물
KR101899773B1 (ko) * 2017-03-07 2018-09-18 일동제약(주) 베시포비르 디피복실 또는 이의 약제학적 허용되는 염 함유 과립, 상기 과립을 포함하는 약제학적 조성물 및 이의 제조 방법
KR20250114822A (ko) 2024-01-22 2025-07-29 변현주 고객의 안면 영상 촬영에 의한 주류 판매 방법 및 그 주류 판매 시스템

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887481A (en) * 1957-04-29 1959-05-19 Schering Corp Heterocyclic amides
US3832460A (en) * 1971-03-19 1974-08-27 C Kosti Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
EP0670319A4 (en) * 1992-11-20 1996-01-17 Thaisho Pharmaceutical Co Ltd HETEROCYCLIC COMPOUNDS.
EP0620222A3 (en) * 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6624138B1 (en) * 2001-09-27 2003-09-23 Gp Medical Drug-loaded biological material chemically treated with genipin
MY141789A (en) 2001-01-19 2010-06-30 Lg Chem Investment Ltd Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same.
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
RU2005108601A (ru) * 2002-09-26 2006-01-20 Эл Джи Лайф Сайенсиз Лтд. (Kr) (+)-транс-изомеры(1-фосфонометокси-2-алкилциклопропил)метилнуклеозидные производные, способ получения их стереоизомеров и применение указанных соединений в качестве противовирусных средств
WO2004029049A1 (ja) * 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. 2-アシルアミノチアゾール誘導体の新規な塩
US7444183B2 (en) * 2003-02-03 2008-10-28 Enteromedics, Inc. Intraluminal electrode apparatus and method
NZ546001A (en) * 2003-10-02 2009-09-25 Pharmacia & Upjohn Co Llc Salts and polymorphs of a pyrrole-substituted indolinone compound
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
JP2007523180A (ja) * 2004-02-17 2007-08-16 エルジー・ライフ・サイエンシーズ・リミテッド Hiv感染治療に有用なヌクレオシドホスホネート誘導体
EP1740539A2 (en) * 2004-04-26 2007-01-10 Teva Pharmaceutical Industries Ltd Preparation of tegaserod and tegaserod maleate
KR101033290B1 (ko) * 2004-07-02 2011-05-09 주식회사 엘지생명과학 다이아이소프로필((1-(하이드록시메틸)-사이클로프로필)옥시)메틸포스포네이트의 새로운 제조 방법
DE102005034974A1 (de) * 2005-07-22 2007-04-19 Grünenthal GmbH Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen
AU2006277742B2 (en) * 2005-08-08 2010-08-26 Pfizer Inc. Salts and polymorphs of a VEGF-R inhibitor
PE20070717A1 (es) * 2005-11-08 2007-08-17 Millennium Pharm Inc Sal de maleato y polimorfo de [2-({4-[(dimetilamino)iminometil]fenil}carbonilamino)-5-metoxifenil]-n-(5-cloro-(2-piridil))carboxamida
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
JP2010504978A (ja) * 2006-09-29 2010-02-18 アイデニクス ファーマシューティカルズ,インコーポレーテッド Hiv阻害剤としての鏡像異性的に純粋なホスホインドール

Also Published As

Publication number Publication date
CA2673510C (en) 2012-08-21
MX2009006826A (es) 2009-07-02
TW200836744A (en) 2008-09-16
EA200970690A1 (ru) 2009-12-30
EA015269B1 (ru) 2011-06-30
JP4980431B2 (ja) 2012-07-18
TWI384986B (zh) 2013-02-11
CO6210809A2 (es) 2010-10-20
CL2008000070A1 (es) 2008-07-25
WO2008088147A1 (en) 2008-07-24
KR100935904B1 (ko) 2010-01-07
US20090325904A1 (en) 2009-12-31
AR064915A1 (es) 2009-05-06
JP2010516668A (ja) 2010-05-20
CN101616674B (zh) 2012-06-13
BRPI0806461B1 (pt) 2019-09-03
BRPI0806461A2 (pt) 2011-09-06
KR20080067969A (ko) 2008-07-22
CN101616674A (zh) 2009-12-30
EP2124953A1 (en) 2009-12-02
UA91655C2 (ru) 2010-08-10
EP2124953A4 (en) 2011-02-09
MY163479A (en) 2017-09-15
CA2673510A1 (en) 2008-07-24
ZA200904378B (en) 2010-05-26

Similar Documents

Publication Publication Date Title
BRPI0806461B8 (pt) monossal do ácido maleico, e, composição farmacêutica para a prevenção ou tratamento das infecções virais
CY1122291T1 (el) Αναστολeις ιικου αναδιπλασιασμου
MX2010009995A (es) Heterociclos puenteados como inhibidores de la integrasa del virus de inmunodeficiencia humana.
PH12013501955A1 (en) Viral inhibitor composition for in vivo therapeutic use
UA103881C2 (ru) Профилактика или терапевтическое лечение инфекции, вызванной вирусом иммунодефицита человека
SG178952A1 (en) Chemical compounds
WO2008002959A3 (en) Hiv integrase inhibitors
ECSP13012418A (es) Derivados de ácido 2-quinolin-acético como compuestos antivirales para vih
CY1111702T1 (el) Τα παραγωγα ινδολης ως αγωνιστες υποδοχεων s1p1
MX348481B (es) Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas.
DOP2011000343A (es) Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
MX346186B (es) Inhibidores de proteina cinasas.
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
MY148807A (en) Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
MX2011011776A (es) Nuevos profarmacos de triptolite.
NZ733313A (en) Indole derivatives as dengue viral replication inhibitors
PH12012502082A1 (en) Combination of active loaded granules with additional actives
MX2009008495A (es) Novedosos analogos de nucleosidos para el tratamiento de infecciones virales.
CL2008002384A1 (es) Compuestos derivados de quinoliniloxipiperidina y pirrolidina, composicion farmaceutica, combinacion farmaceutica, util para el tratamiento de enfermedades inflamatorias y/o alergicas del tracto respiratorio.
IL203873A0 (en) Novel targets and compounds for therapeutic intervention of hiv infection
WO2008116663A3 (en) Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments
ATE500236T1 (de) Mit lanthionin verwandte verbindungen zur behandlung entzündlicher krankheiten
BR112012024522A2 (pt) combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
WO2008154246A8 (en) Hiv integrase inhibitors

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: LG LIFE SCIENCES LTD. (KR)

B25G Requested change of headquarter approved

Owner name: LG LIFE SCIENCES LTD. (KR)

B25A Requested transfer of rights approved

Owner name: LG CHEM, LTD (KR)

B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/01/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF